The EGFR Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 786-O human clear cell renal cell carcinoma line, with targeted disruption of the EGFR gene. This knockout model enables loss-of-function studies of epidermal growth factor receptor signaling in a cellular background pertinent to renal cell carcinoma and other EGFR-dependent malignancies. The polyclonal population reflects a heterogeneous knockout, allowing investigation of pooled effects on signaling networks and cellular behavior.
The 786-O cell line was established from a primary human clear cell renal cell carcinoma and is widely used to study ccRCC biology. These cells exhibit typical characteristics of renal carcinoma, including VHL gene alterations, and provide a genetically relevant platform for exploring oncogenic pathways. As a ccRCC model, 786-O cells are responsive to growth factors and serve as a standard host for investigating tumor cell proliferation, migration, and drug responses.
EGFR encodes a receptor tyrosine kinase that, upon binding of ligands such as EGF, TGF-??, amphiregulin, epiregulin, betacellulin, or HB-EGF, undergoes dimerization and autophosphorylation. Phosphotyrosine residues recruit adaptor proteins GRB2 and SHC, promoting nucleotide exchange on RAS through SOS. Activated RAS stimulates the RAF-MEK-ERK cascade, leading to phosphorylation of ERK and transcriptional induction of immediate-early genes including c-FOS, c-JUN, and MYC. Concurrently, GAB1 recruits PI3K, generating PIP3 and activating AKT and mTOR, which drive cell survival and metabolism. EGFR also signals through JAK2 to phosphorylate STAT3 and STAT5, and via PLC?? to trigger calcium and PKC pathways. These integrated networks coordinate proliferation, differentiation, apoptosis, and migration.
In renal cell carcinoma, EGFR overexpression and aberrant signaling are frequently observed and have been linked to tumor progression, metastasis, and resistance to targeted therapies. The 786-O polyclonal EGFR knockout cells facilitate dissection of EGFR-dependent versus -independent mechanisms in ccRCC. By ablating EGFR, researchers can explore compensatory signaling through other ErbB family members such as ErbB2, ErbB3, or ErbB4, or assess the reliance of downstream effectors like ERK and AKT on EGFR input. This model is particularly valuable for identifying synthetic lethal interactions and novel therapeutic strategies in renal cancer.
These polyclonal knockout cells support a range of research applications including investigation of cancer signaling, drug resistance mechanisms, and functional genomics. They are suitable for assays such as Western blotting and RT-qPCR to validate EGFR disruption, proliferation and migration assays to measure phenotypic consequences, phospho-ERK and phospho-AKT immunoblotting to monitor pathway activity, apoptosis assays to evaluate cell death, and drug sensitivity testing to uncover dependencies. Applications extend to identification of potential therapeutic targets and preclinical evaluation of kinase inhibitors. For further information, please contact Ascent Research.
